Roger Bruggemann, Pharm, PhD

PharmD, PhD
Radboud university medical centre, Netherlands

Disclosure(s): Amplyx: Advisor/Consultant; Astellas: Advisor/Consultant; Cidara: Advisor/Consultant; Gilead: Advisor/Consultant, Grant; Mindipharma: Advisor/Consultant; Pfizer: Advisor/Consultant, Grant

Poster(s):

• 595 - Olorofim (OLO) for treatment of invasive mould infections in patients with limited or no treatment options: PK data from a Phase 2b open-label study (NCT03583164, Study 32)
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET